LIPO
Lipella Pharmaceuticals Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.00
+0.00%Income statement
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 173.7K | 536.4K | 449.6K | 184.2K | 259.3K |
| Cost of Revenue | 3.6M | 3.6M | 3.0M | 2.5M | 1.5M |
| Gross Profit | (3.4M) | (3.1M) | (2.6M) | (2.4M) | (1.2M) |
| Operating Expenses | |||||
| R&D Expense | 1.1M | 3.6M | 3.0M | 2.5M | 1.5M |
| SG&A Expense | 2.2M | 2.0M | 2.2M | 226.2K | 718.4K |
| General & Admin Expense | 2.2M | 2.0M | 2.2M | 226.2K | 718.4K |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (1.3M) | (3.6M) | (3.0M) | (2.5M) | (1.5M) |
| Total Operating Expenses | 2.0M | 2.0M | 2.2M | 226.2K | 718.4K |
| Cost and Expenses | 5.6M | 5.6M | 5.2M | 2.8M | 2.2M |
| Operating Income (EBIT) | (5.4M) | (5.1M) | (4.7M) | (2.6M) | (1.9M) |
| Non-Operating | |||||
| Interest Income | 80.2K | 64.3K | 137.8K | 1.7K | 104.00 |
| Interest Expense | — | — | 10.8K | 9.6K | 6.8K |
| Net Interest Income | 80.2K | 64.3K | 127.0K | (7.9K) | (6.7K) |
| Other Non-Op Income/Expense | 80.2K | 64.3K | 127.0K | (8.0K) | 50.4K |
| Non-Operating Income (excl Interest) | (80.2K) | (64.3K) | (137.8K) | (1.6K) | (57.2K) |
| EBT (Pre-Tax Income) | (5.3M) | (5.0M) | (4.6M) | (2.6M) | (1.9M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (5.3M) | (5.0M) | (4.6M) | (2.6M) | (1.9M) |
| Earnings from Cont. Ops | (5.3M) | (5.0M) | (4.6M) | (2.6M) | (1.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (5.3M) | (5.0M) | (4.6M) | (2.6M) | (1.9M) |
| Per Share | |||||
| Basic EPS | ($2.60) | ($4.79) | ($6.16) | ($5.12) | ($4.38) |
| Diluted EPS | ($2.60) | ($4.79) | ($6.16) | ($5.12) | ($4.38) |
| Revenue Per Share | $0.04 | $0.51 | $0.60 | $0.36 | $0.61 |
| Shares | |||||
| Basic Shares Outstanding | 4.5M | 1.0M | 749832 | 507361 | 426006 |
| Diluted Shares Outstanding | 4.5M | 1.0M | 750384 | 507578 | 426006 |
| Profitability Metrics | |||||
| EBITDA | (5.3M) | (5.0M) | (4.6M) | (2.6M) | (1.9M) |
| D&A | 2.9K | 2.9K | 1.7K | — | — |
| EBIT | (5.3M) | (5.0M) | (4.6M) | (2.6M) | (1.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2025